Obesity Drug's Mid-Stage Win; Endocrine Disease Disparities; Chewing Away Diabetes?

(MedPage Today) -- An investigational dual glucagon/GLP-1 receptor agonist helped people with obesity or overweight, but without diabetes, shed about 15% of their body weight by 46 weeks in a phase II trial, Boehringer Ingelheim and Zealand Pharma...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news